Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment.

Abstract

AIMS:

Novel anticancer strategies have employed bacteriophages as drug carriers and display platforms for anticancer agents; however, bacteriophage-based platforms maintain their natural antibacterial activity. This study provides the assessment of combined anticancer (engineered) and antibacterial (natural) phage activity in therapies.

MATERIALS & METHODS:

An in vivo BALB/c mouse model of 4T1 tumor growth accompanied by surgical wound infection was applied. The wounds were located in the areas of tumors. Bacteriophages (T4) were modified with anticancer Tyr-Ile-Gly-Ser-Arg (YIGSR) peptides by phage display and injected intraperitoneally.

RESULTS & CONCLUSION:

Tumor growth was decreased in mice treated with YIGSR-displaying phages. The acuteness of wounds, bacterial load and inflammatory markers in phages-treated mice were markedly decreased. Thus, engineered bacteriophages combine antibacterial and anticancer activity.

• Authors: Krystyna Dąbrowska, Zuzanna Kaźmierczak, Joanna Majewska, Paulina Miernikiewicz, Agnieszka Piotrowicz, Joanna Wietrzyk, Dorota Lecion, Katarzyna Hodyra, Anna Nasulewicz-Goldeman, Barbara Owczarek, Andrzej Górski
• Journal: Future microbiology (Future Microbiol) Vol. 9 Issue 7 Pg. 861-9 ( 2014) ISSN: 1746-0921 [Electronic] England
• PMID: 25156375 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Antineoplastic Agents
• Peptides

Topics

• Animals
• Anti-Bacterial Agents (administration & dosage, metabolism)
• Antineoplastic Agents (administration & dosage, metabolism)
• Bacterial Infections (therapy)
• Bacteriophage T4 (genetics, metabolism)
• Biological Therapy
• Drug Delivery Systems (methods)
• Escherichia coli (virology)
• Female
• Gene Expression
• Humans
• Mice
• Mice, Inbred BALB C
• Neoplasms (drug therapy)
• Peptides (administration & dosage, genetics, metabolism)